Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.61 |
| ▸ | MEF2D | Q14814 | 3/20 | 0.61 |
| ▸ | HTR6 | P50406 | 5/20 | 0.56 |
| ▸ | HTR1A | P08908 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.53 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.53 |
| ▸ | HTR3B | O95264 | 2/20 | 0.53 |
| ▸ | HTR3A | P46098 | 2/20 | 0.53 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.53 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964227 | 0.83 | HDAC4 (0.60) | HDAC4MEF2DHTT | |
| SCHEMBL8985943 | 0.81 | ADRB1 (0.57) | HDAC4MEF2DHTR6HTR1AHTR7 | |
| SCHEMBL30438836 | 0.78 | PRMT6 (0.63) | HDAC4MEF2DTP53CYP1A2CYP3A4 | |
| SCHEMBL21232408 | 0.77 | HDAC4 (1.00) | HDAC4MEF2D | |
| SCHEMBL846265 | 0.77 | ACHE (0.65) | HTR6MAOBACHENTRK1ROCK1 | |
| SCHEMBL1963799 | 0.77 | HDAC4 (0.43) | HDAC4MEF2DHTR1AHTR7HTR2C | |
| Hydrochloric Acid SCHEMBL1588080 | 0.76 | ACHE (0.64) | HTR6MAOBACHENTRK1ROCK1 | |
| SCHEMBL13345895 | 0.75 | HTR7 (0.57) | HDAC4MEF2DHTR6HTR1AHTR7 | |
| SCHEMBL6264215 | 0.75 | ADRB1 (0.62) | HTR6HTR1AHTR7ADRB1HTR3E | |
| SCHEMBL5072298 | 0.75 | HTR7 (0.54) | HDAC4MEF2DHTR6HTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | disclosed |
| CN-101203500-B | Substituted arylamine compounds and their use as 5-HT6Use of modulators | GALENEA CORP | 2013-08-21 | — | — | CN | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| EP-2037925-B1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | GALENEA CORP (US) | 2012-02-01 | — | — | EP | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100152141-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | EPIX DELAWARE, INC (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2037925-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | Epix Delaware, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| CN-101203500-A | Substituted arylamine compounds and their use as 5-HT6Use of modulators | EPIX DELAWARE INC (US) | 2008-06-18 | — | — | CN | disclosed |
| WO-2008002539-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | EPIX DELAWARE, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| EP-1590329-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | Aventis Pharma S.A. (FR) | 2005-11-02 | — | — | EP | disclosed |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AVENTIS PHARMA S. A. (FR) | 2005-06-16 | — | — | US | disclosed |
| WO-2004078732-A1 | N-ARYL HETEROAROMATIC PRODUCTS, COMPOSITIONS CONTAINING SAME AND USE THEREOF | AVENTIS PHARMA S.A. (FR) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152141-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | HTR6, HTR3B, HTR1B | HDAC4 1031/4885MEF2D 4161/4885HTR6 1/4885 |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | HDAC4 1039/4885MEF2D 1801/4885HTR6 1/4885 |
| US-20050130989-A1 | N-arylheteroaromatic products compositions containing them and use thereof | AHR, NQO1, ARNT | HDAC4 1146/4885MEF2D 4049/4885HTR6 3115/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | HDAC4 1039/4885MEF2D 1801/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.